GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (NAS:RDHL) » Definitions » Shiller PE Ratio

Redhill Biopharma (Redhill Biopharma) Shiller PE Ratio : (As of Apr. 29, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Redhill Biopharma Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Redhill Biopharma Shiller PE Ratio Historical Data

The historical data trend for Redhill Biopharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma Shiller PE Ratio Chart

Redhill Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Redhill Biopharma Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Redhill Biopharma's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Redhill Biopharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Redhill Biopharma's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Redhill Biopharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Redhill Biopharma's Shiller PE Ratio falls into.



Redhill Biopharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Redhill Biopharma's E10 for the quarter that ended in Jun. 2023 is calculated as:

For example, Redhill Biopharma's adjusted earnings per share data for the three months ended in Jun. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=0.193/128.7287*128.7287
=0.193

Current CPI (Jun. 2023) = 128.7287.

Redhill Biopharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201309 -16.000 98.790 -20.849
201312 -20.000 98.326 -26.184
201403 16.000 99.695 20.660
201406 -20.000 100.560 -25.602
201409 -24.000 100.428 -30.763
201412 -24.000 99.070 -31.185
201503 -20.000 99.621 -25.844
201506 -28.000 100.684 -35.799
201509 -16.000 100.392 -20.516
201512 -20.643 99.792 -26.629
201603 -16.000 100.470 -20.500
201606 -24.000 101.688 -30.382
201609 -28.000 101.861 -35.386
201612 -28.000 101.863 -35.385
201703 -20.000 102.862 -25.029
201706 -24.000 103.349 -29.894
201709 -36.000 104.136 -44.502
201712 -20.000 104.011 -24.753
201803 -20.000 105.290 -24.452
201806 -20.000 106.317 -24.216
201809 -16.000 106.507 -19.338
201812 -12.000 105.998 -14.573
201903 -12.000 107.251 -14.403
201906 -16.000 108.070 -19.059
201909 -12.000 108.329 -14.260
201912 -12.000 108.420 -14.248
202003 -20.000 108.902 -23.641
202006 -16.000 108.767 -18.936
202009 -20.000 109.815 -23.445
202012 -28.000 109.897 -32.798
202103 -20.000 111.754 -23.038
202106 -24.000 114.631 -26.952
202109 -20.000 115.734 -22.246
202112 -20.000 117.630 -21.887
202203 -16.000 121.301 -16.980
202206 -8.000 125.017 -8.238
202209 -24.000 125.227 -24.671
202212 0.000 125.222 0.000
202303 20.000 127.348 20.217
202306 0.193 128.729 0.193

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Redhill Biopharma  (NAS:RDHL) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Redhill Biopharma Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Redhill Biopharma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Redhill Biopharma (Redhill Biopharma) Business Description

Traded in Other Exchanges
Address
21 Ha’arba’a Street, Tel Aviv, ISR, 6473921
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.